Company profile: AroCell
1.1 - Company Overview
Company description
- Provider of biomarker-based diagnostic tests for cancer prognosis, monitoring, and follow-up, including the TK 210 ELISA measuring TK1 as a marker of increased cell turnover. Offers Oncology Diagnostics tools to capture critical clinical data for cancer patient management, and TUBEX TF, a rapid, sensitive in vitro test for detecting acute typhoid fever caused by Salmonella enterica.
Products and services
- Oncology Diagnostics: Arocell architects biomarker-driven diagnostic products that capture critical clinical data to support prognosis, monitoring, and follow-up in cancer patient management, focusing on tumor cell turnover biomarkers
- TK 210 ELISA: Arocell engineers an ELISA-based test measuring TK1 enzyme levels in blood, reflecting increased cell turnover (cell growth and death) for cancer prognosis, monitoring, and follow-up
- TUBEX® TF: Arocell delivers an in vitro diagnostic test providing rapid and sensitive detection of acute typhoid fever caused by Salmonella enterica
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AroCell
SmartHealth Dx
HQ: United States
Website
- Description: Provider of precision diagnostics addressing unmet clinical needs in vascular, metabolic, and oncological diseases, including SmartVascular Dx (blood test for vascular inflammation and stroke risk), SmartLung Dx (noninvasive test to identify benign lung nodules), SmartKidney Dx (metastasis risk in kidney disease), SmartScience Dx (~195,000-sample serum repository for biomarker discovery), and SmartPath Dx (real-time pathology imaging).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SmartHealth Dx company profile →
Sorrento Therapeutics
HQ: United States
Website
- Description: Provider of proprietary drug therapeutics under development to address unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sorrento Therapeutics company profile →
Notable
HQ: United States
Website
- Description: Provider of personalized drug combination testing for cancer patients and a Predictive Medicine Platform (PMP) that predicts patient response to specific therapies to identify responsive patients before treatment. Develops therapeutics, including Presponse Therapeutics and the PLK-1 inhibitor volasertib, with development guided by predictive patient response data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Notable company profile →
Calistoga Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutic oral medicines targeting selected isoforms of the PI3K pathway to improve the health of patients with cancer and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calistoga Pharmaceuticals company profile →
TomoTherapy
HQ: United States
Website
- Description: Provider of advanced radiation therapy solutions that are developed, manufactured, distributed, marketed and sold for treating a wide variety of cancers. Its ring gantry-based TomoTherapy platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TomoTherapy company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AroCell
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AroCell
2.2 - Growth funds investing in similar companies to AroCell
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AroCell
4.2 - Public trading comparable groups for AroCell
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →